Innate Pharma S.A. (LON:0EVI)

Market Cap	152.44M
Revenue (ttm)	28.65M
Net Income (ttm)	-28.87M
Shares Out	n/a
EPS (ttm)	-0.36
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	691
Average Volume	3,855
Open	2.118
Previous Close	2.070
Day's Range	2.080 - 2.200
52-Week Range	1.149 - 2.307
Beta	0.79
RSI	70.07
Earnings Date	Mar 27, 2025

About Innate Pharma

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head an...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 179
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0EVI

Financial Performance

In 2023, Innate Pharma's revenue was 61.64 million, an increase of 6.88% compared to the previous year's 57.67 million. Losses were -7.57 million, -86.97% less than in 2022.

Financial numbers in EUR